Reading view
DF-ACBlurGAN: Structure-Aware Conditional Generation of Internally Repeated Patterns for Biomaterial Microtopography Design
Pathogenesis and immune regulation of rheumatoid arthritis-associated interstitial lung disease: from basic research to clinical implications
Front Immunol. 2026 Mar 13;17:1770348. doi: 10.3389/fimmu.2026.1770348. eCollection 2026.
ABSTRACT
Interstitial lung disease (ILD) is one of the most common extra-articular manifestations of rheumatoid arthritis (RA). Some patients with RA-ILD may develop progressive pulmonary fibrosis, leading to severe impairment of lung function and respiratory failure, which impacts quality of life and can even be life-threatening. This review identified genetic susceptibility, environmental factors, and immune dysregulation as key contributors to the etiology and pathogenesis of RA-ILD. We highlight that autoantibodies, adaptive immune abnormalities, and tertiary lymphoid organ formation significantly drive pulmonary inflammation and fibrosis, while pro-inflammatory cytokines and epithelial-mesenchymal transition (EMT) further contribute to lung tissue injury. Current treatment options, including glucocorticoids, immunosuppressants, and antifibrotic agents such as nintedanib and pirfenidone, are often limited by substantial side effects. Additionally, emerging therapies like JAK inhibitors, CAR-T cells, and the upcoming phosphodiesterase-4B inhibitor, nerandomilast, show promise, but no curative treatment exists to date. Future research could focus on multi-omics technologies and conducting multicenter clinical trials to establish therapeutic targets and advance precision medicine for RA-ILD.
PMID:41909710 | PMC:PMC13021622 | DOI:10.3389/fimmu.2026.1770348
Reasoning over Semantic IDs Enhances Generative Recommendation
Efficient Reasoning with Balanced Thinking
CCMamba: Topologically-Informed Selective State-Space Networks on Combinatorial Complexes for Higher-Order Graph Learning
UIS-Digger: Towards Comprehensive Research Agent Systems for Real-world Unindexed Information Seeking
Mean Flow Policy with Instantaneous Velocity Constraint for One-step Action Generation
CRTAM inhibition mitigates toxicity of immune checkpoint inhibitors without antitumor efficacy trade-off
Nature Cancer, Published online: 05 March 2026; doi:10.1038/s43018-026-01135-0
Dong and colleagues report that blockade of T cell-expressed cytotoxic and regulatory T cell molecule results in selective mitigation of immune-related toxicities without affecting antitumor efficacy of immune checkpoint inhibitors.